EMGALITY 120 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN
Ask a doctor about a prescription for EMGALITY 120 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN
How to use EMGALITY 120 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN
Introduction
Package Leaflet: Information for the Patient
Emgality 120mg solution for injection in pre-filled pen
galcanezumab
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your doctor, pharmacist, or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
Contents of the pack
- What is Emgality and what is it used for
- What you need to know before you use Emgality
- How to use Emgality
- Possible side effects
- Storing Emgality
- Contents of the pack and other information
1. What is Emgality and what is it used for
Emgality contains galcanezumab, a medicine that blocks the activity of a naturally occurring substance in the body called calcitonin gene-related peptide (CGRP). People with migraine may have increased levels of CGRP.
Emgality is used to prevent migraine in adults who have at least 4 days of migraine per month.
Emgality may reduce the frequency of migraine and improve your quality of life. It starts working in about one week.
2. What you need to know before you use Emgality
Do not use Emgality:
- if you are allergic to galcanezumab or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before or during treatment with Emgality if:
- you have severe cardiovascular disease. Emgality has not been studied in patients with severe cardiovascular diseases.
Monitor for allergic reactions
Emgality may potentially cause serious allergic reactions. Serious allergic reactions occur mainly within 1 day after using Emgality, but some reactions may be delayed (occurring more than 1 day and up to 4 weeks after using Emgality). Some allergic reactions can be long-lasting. You should monitor for signs of these reactions while using Emgality. Stop using Emgality and tell your doctor or seek medical attention immediately if you notice any signs of a serious allergic reaction. These signs are listed under “Serious side effects” in section 4.
Children and adolescents
This medicine must not be used in children and adolescents under 18 years because it has not been studied in this age group.
Other medicines and Emgality
Tell your doctor, pharmacist, or nurse if you are using, have recently used, or might use any other medicines.
Pregnancy and breastfeeding
If you are a woman who could become pregnant, you are advised to avoid becoming pregnant while using Emgality.
If you are pregnant, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medicine. It is preferable to avoid the use of Emgality during pregnancy, as the effects of this medicine in pregnant women are not known.
If you are breastfeeding or plan to breastfeed, consult your doctor before using this medicine. You and your doctor must decide whether to breastfeed or use Emgality.
Driving and using machines
Galcanezumab may have a small effect on the ability to drive and use machines. Some patients have experienced dizziness while using Emgality.
Emgality contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per 120 mg dose; this is essentially “sodium-free”.
3. How to use Emgality
Follow the instructions for administration of this medicine exactly as told by your doctor, pharmacist, or nurse. If you are unsure, consult your doctor, pharmacist, or nurse again.
The Emgality pre-filled pen is for single use and contains one dose of Emgality (120 mg).
- The first time you are given Emgality, your doctor or nurse will inject two pens (240 mg in total).
- After the first dose, you will use one pen (120 mg) every month.
Your doctor will decide how long you should use Emgality.
Emgality is given by injection under the skin (subcutaneous injection). You and your doctor or nurse should decide if you can inject Emgality yourself.
It is important that you do not try to inject yourself until you have been trained on how to do it by your doctor or nurse. A caregiver can also give you your Emgality injection if they are properly trained.
The pen must not be shaken.
Read the “Instructions for Use” for the pen carefully before using Emgality.
If you use more Emgality than you should
If you have injected more Emgality than you should, e.g. if after the first dose of 240 mg you have injected the medicine twice in one month, or if someone else has used Emgality accidentally, contact your doctor immediately.
If you forget to use Emgality
Do not inject a double dose to make up for a forgotten injection.
If you have forgotten to inject a dose of Emgality, inject the missed dose as soon as possible and then inject the next dose after one month from that date.
If you stop using Emgality
Do not stop using Emgality without talking to your doctor first.
If you have any other questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects
Generally, allergic reactions with Emgality are mild to moderate (such as rash or itching). Serious allergic reactions can occur rarely (may affect up to 1 in 1000 people) and signs may include:
- difficulty breathing or swallowing,
- low blood pressure, which can cause dizziness or fainting,
- swelling of the neck, face, mouth, lips, tongue, or throat which can develop rapidly,
- severe itching of the skin with rash or hives.
Talk to your doctor or seek medical attention immediately if you notice any of these signs.
Other side effects reported
Very common side effects(may affect more than 1 in 10 people):
- Pain at the injection site
- Injection site reactions (e.g. redness, itching, bruising, swelling)
Common side effects(may affect up to 1 in 10 people):
- Dizziness (a feeling of spinning or dizziness)
- Constipation
- Itching
- Rash
Uncommon side effects(may affect up to 1 in 100 people):
- Hives (rash on the skin with itching)
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storing Emgality
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date is the last day of the month shown.
Store in a refrigerator (2°C to 8°C). Do not freeze.
Store in the original package to protect from light.
Emgality can be left outside the refrigerator for a single period of up to 7 days at a temperature not above 30°C. The pen should be discarded if stored at a temperature higher or for a longer period.
Do not use this medicine if you notice that the pen is damaged or the medicine appears cloudy or has particles in it.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
6. Contents of the pack and other information
What Emgality contains
- The active substance is galcanezumab. Each pre-filled pen contains 120 mg of galcanezumab in 1 ml of solution.
- The other ingredients are: L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, sodium chloride, and water for injections.
Appearance and pack contents
Emgality is a solution for injection in a clear glass syringe. Its color may vary from colorless to slightly yellow.
The syringe is inserted into a single-use disposable pen. Pack sizes of 1, 2, or 3 pre-filled pens.
Not all pack sizes may be marketed.
Marketing authorisation holder
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, Netherlands.
Manufacturer
Eli Lilly Italia S.p.A., Via Gramsci 731/733, 50019, Sesto Fiorentino (FI), Italy.
Lilly, S.A., Avda. de la Industria, 30, 28108 Alcobendas, Madrid, Spain.
You can ask for more information about this medicine from the representative of the marketing authorisation holder:
Belgium/België/Belgien Eli Lilly Benelux S.A./N.V. Tel: + 32-(0)2 548 84 84 | Lithuania Eli Lilly Lietuva Tel: +370 (5) 2649600 |
| Luxembourg/Luxemburg Eli Lilly Benelux S.A./N.V. Tel: + 32-(0)2 548 84 84 |
Czech Republic ELI LILLY CR, s.r.o. Tel: + 420 234 664 111 | Hungary Lilly Hungária Kft. Tel: + 36 1 328 5100 |
Denmark Eli Lilly Danmark A/S Tel: +45 45 26 60 00 | Malta Charles de Giorgio Ltd. Tel: + 356 25600 500 |
Germany Lilly Deutschland GmbH Tel: + 49-(0) 6172 273 2222 | Netherlands Eli Lilly Nederland B.V. Tel: + 31-(0) 30 60 25 800 |
Estonia Eli Lilly Nederland B. V. Tel: +372 6 817 280 | Norway Eli Lilly Norge A.S. Tel: + 47 22 88 18 00 |
Greece ΦΑΡΜΑΣΕΡΒ-ΛΙΛΛΥ Α.Ε.Β.Ε. Tel: +30 210 629 4600 | Austria Eli Lilly Ges.m.b.H. Tel: + 43-(0) 1 711 780 |
Spain Organon Salud, S.L. Tel: +34 91 591 12 79 | Poland Eli Lilly Polska Sp. z o.o. Tel: +48 22 440 33 00 |
France Organon France Tel: +33-(0) 1 57 77 32 00 | Portugal Lilly Portugal Produtos Farmacêuticos, Lda Tel: + 351-21-4126600 |
Croatia Eli Lilly Hrvatska d.o.o. Tel: +385 1 2350 999 | Romania Eli Lilly România S.R.L. Tel: + 40 21 4023000 |
Ireland Eli Lilly and Company (Ireland) Limited Tel: + 353-(0) 1 661 4377 | Slovenia Eli Lilly farmacevtska družba, d.o.o. Tel: +386 (0)1 580 00 10 |
Iceland Icepharma hf. Tel: + 354 540 8000 | Slovakia Eli Lilly Slovakia s.r.o. Tel: + 421 220 663 111 |
Italy Eli Lilly Italia S.p.A. Tel: + 39- 055 42571 | Finland Oy Eli Lilly Finland Ab Tel: + 358-(0) 9 85 45 250 |
Cyprus Phadisco Ltd Tel: +357 22 715000 | Sweden Eli Lilly Sweden AB Tel: + 46-(0) 8 7378800 |
Latvia Eli Lilly (Suisse) S.A Parstavnieciba Latvija Tel: +371 67364000 | United Kingdom(Northern Ireland) Eli Lilly and Company (Ireland) Limited Tel: + 353-(0) 1 661 4377 |
Date of last revision of this leaflet:
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/.
Instructions for use Emgality 120mg solution for injection in pre-filled pen galcanezumab | |
For subcutaneous use | |
| |
Before using your pre-filled pen (pen): | |
Important Information | |
| |
| |
| |
| |
INSTRUCTIONS FOR USE Before using the Emgality pen, carefully read and follow all the step-by-step instructions. |
Parts of the Emgality pen
|
|
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a licensed doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to EMGALITY 120 mg SOLUTION FOR INJECTION IN A PRE-FILLED PENDosage form: INJECTABLE, 120 mgActive substance: galcanezumabManufacturer: Eli Lilly Nederland B.V.Prescription requiredDosage form: INJECTABLE, 140 mgActive substance: erenumabManufacturer: Novartis Europharm LimitedPrescription requiredDosage form: INJECTABLE, 70 mgActive substance: erenumabManufacturer: Novartis Europharm LimitedPrescription required
Online doctors for EMGALITY 120 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for EMGALITY 120 mg SOLUTION FOR INJECTION IN A PRE-FILLED PEN – subject to medical assessment and local rules.
Get updates and exclusive offers
Be the first to know about new services, marketplace updates, and subscriber-only promos.
